Johnson & Johnson (JNJ) Sees Nipocalimab as Underappreciated with >$1B in Peak Sales - Credit Suisse
Tweet Send to a Friend
Credit Suisse analyst Matt Miksic reiterated an Outperform rating and $163.00 price target on Johnson & Johnson (NYSE: JNJ) noting ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
